Skip to main content

Valliant John's Form 4 filing

Fusion Pharmaceuticals Inc. (FUSN) · filed Feb 23, 2022

Accession no.
0001209191-22-012344
Filed
Feb 23, 2022
Trade date
Feb 18-23, 2022
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $298.4K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Valliant JohnCIK 0001813574Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 18, 2022Common StockSSaleDisposed−4,898$7.88F2−$38,596.24479,534Direct
Feb 22, 2022Common StockSSaleDisposed−4,100$7.85F3−$32,185475,434Direct
Feb 23, 2022Common StockSSaleDisposed−29,299$7.77F4−$227,653.23446,135Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.66 to $8.04 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.67 to $7.98 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.47 to $8.00 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)